2020-11-12T13:19:24-06:00 2019-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2019-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 BRIAN NEVILLE VP ACCOUNTING/FINANCIAL OPERATIONS 2062853500 2020-11-12 1 RICHARD J LOCASTRO CPA P00288314 3019519090 75.103.231.202 2020-11-12 14:19:18 ES P FF16D77653F3D7C4C20B8532A1D3BA36122446EB 5AB07A053B3A330C0D5964923757432F9BB68C3B 2019 2021-01-29 14:40:06Z BRIAN NEVILLE 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 11747531 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 9 2 0 0 0 0 34948159 9933910 0 0 844490 1027353 14669 0 35807318 10961263 23787777 7606129 0 0 0 0 0 0 0 11603798 2140262 35391575 9746391 415743 1214872 38472788 38989543 37875254 36842677 597534 2146866 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-RESOURCE SETTINGS BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST. (CONTINUED ON SCHEDULE O)FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT. FOR THESE PARTNERS, PVS PROVIDES FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, REGULATORY, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE SETTINGS. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN PUBLIC IMMUNIZATION PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES. 0 0 9746391 7606129 IN 2019, PVS CONTINUED OUR FIGHT AGAINST DIARRHEAL DISEASES, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LOW-INCOME COUNTRIES. TO COMBAT ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, WE CONTINUED CLINICAL DEVELOPMENT OF A NONREPLICATING ROTAVIRUS VACCINE CANDIDATE BY BEGINNING A PHASE 3 EFFICACY STUDY IN ZAMBIA, THE FIRST OF FOUR COUNTRIES PARTICIPATING IN THIS STUDY. THIS VACCINE CANDIDATE IS ADMINISTERED AS AN INTRAMUSCULAR INJECTION AND COULD POTENTIALLY OVERCOME THE LOWER EFFICACY LEVELS SEEN IN LOW-RESOURCE SETTINGS FOR ORAL, LIVE ATTENUATED ROTAVIRUS VACCINES. (CONTINUED ON SCHEDULE O).IN ADDITION, PVS HOSTED A MEETING IN GENEVA IN JUNE 2019 THAT BROUGHT TOGETHER VACCINE DEVELOPERS AND MANUFACTURERS ENGAGED IN NEXT-GENERATION ROTAVIRUS VACCINE RESEARCH AND DEVELOPMENT TO BETTER DEFINE THE PROGRESS OF THESE NOVEL VACCINE CANDIDATES. FINALLY, PVS INITIATED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL.PVS CONTINUED TO CONDUCT EARLY-STAGE CLINICAL TRIALS OF VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, LEADING CAUSES OF BACTERIAL DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. IN 2019, OUR WORK INCLUDED CONDUCTING A PHASE 1 TRIAL OF AN ORAL, SUBUNIT ETEC VACCINE CANDIDATE GIVEN WITH AND WITHOUT A NOVEL MUCOSAL ADJUVANT. IN 2019 WE ADVANCED DEVELOPMENT OF A LOW-COST VACCINE TO PROTECT CHILDREN AGAINST PNEUMOCOCCAL BACTERIA, THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA. AFTER POSITIVE CLINICAL TRIAL RESULTS IN THE GAMBIA AND INDIA, THE VACCINE PRODUCED BY SERUM INSTITUTE OF INDIA PVT. LTD., PNEUMOSIL, ACHIEVED WORLD HEALTH ORGANIZATION PREQUALIFICATION, CERTIFYING ITS ELIGIBILITY FOR PROCUREMENT BY UNITED NATIONS AGENCIES FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES.PVS, AS PART OF THE ADVANCING MATERNAL IMMUNIZATION (AMI) COALITION, ADDED TO THE RESPIRATORY SYNCYTIAL VIRUS (RSV) MATERNAL IMMUNIZATION KNOWLEDGE BASE IN 2019. THE COALITION PUBLISHED SEVERAL ARTICLES ABOUT THE RESULTS OF AND METHODS USED BY AMI TO DEVELOP A ROAD MAP OUTLINING ACTIVITIES NECESSARY TO MOVE RSV DECISION-MAKING AND DELIVERY FORWARD. AMI ALSO CONTRIBUTED A CHAPTER ON THE STATE OF MATERNAL IMMUNIZATION TO A BOOK FOR THE INDIAN ACADEMY OF PEDIATRICS. COALITION MEMBERS ATTENDED THE 2019 WOMEN DELIVER CONFERENCE IN VANCOUVER, BRITISH COLUMBIA, AND HOSTED A DINNER TO ENGAGE GLOBAL MATERNAL HEALTH LEADERS AND DECISION-MAKERS IN CONVERSATIONS AROUND RSV MATERNAL IMMUNIZATION. AMI ALSO UPDATED ITS RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT (WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE) AND TRIAL TRACKER (WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS) TO ENSURE ACCESS TO THE MOST UP-TO-DATE RSV INFORMATION. 9746391 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 9 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X BRIAN NEVILLE VP ACCOUNTINGFINANCIAL OPERATIONS 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS CHAIR AND PRESIDENT 1.00 39.00 X X 0 560672 64002 DAVID C KASLOW VICE CHAIR 1.00 39.00 X X 0 383540 66181 BRIAN N NEVILLE SECRETARY & TREASURER 1.00 39.00 X X 0 223677 34710 OLIVIA D POLIUS TREASURER 1.00 39.00 X X 0 348833 31967 EDWARD M YOSHIDA SECRETARY 1.00 39.00 X X 0 139711 18277 JERRY KUO DIRECTOR 1.00 39.00 X 0 215587 55953 PRAVEEN RAJA DIRECTOR 1.00 39.00 X 0 408540 39837 ANITA ZAIDI DIRECTOR 1.00 0.00 X 0 0 0 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 0 2280560 310927 0 0 1 0 0 92478 9841432 9933910 839887 839887 973734 786268 187466 187466 187466 10961263 0 0 1027353 4601287 4601287 3004842 3004842 2636 2636 1036 1036 57079 57079 95692 95692 51406 51406 9637 9637 240379 240379 43407 43407 21501 21501 40598 40598 SUBCONTRACTORS 1465029 1465029 STORAGE 44695 44695 LAB SUPPLIES 32206 32206 EQUIPMENT R&M 14429 14429 20532 20532 9746391 9746391 0 0 1111 1054 814380 -14 58 294849 273079 43271 21770 37614040 38966661 38472788 38989543 37875254 36842677 37875254 36842677 X 118341 2125096 479193 21770 597534 2146866 38472788 38989543 1214872 334460 0 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 9746391 0 1 9746391 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 294849 273079 21770 21770 1 CENTRAL AMERICA & THE CARIBBEAN 0 0 PROGRAM MEDICINE ESSENTIAL MEDICINE 22356 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 42992 EAST ASIA AND THE PACIFIC 0 3 PROGRAM SERVICES ESSENTIAL MEDICINE 77653 EUROPE 0 0 GRANTMAKING 2789491 EUROPE 0 4 PROGRAM SERVICES ESSENTIAL MEDICINE 868654 NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 13354 SOUTH AMERICA 0 0 GRANTMAKING 12840 SOUTH ASIA 0 0 GRANTMAKING 142894 SOUTH ASIA 0 2 PROGRAM SERVICES ESSENTIAL MEDICINE 201530 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 16625 SUB-SAHARAN AFRICA 0 1 PROGRAM SERVICES ESSENTIAL MEDICINE 24064 0 7 0 3 0 10 3970234 242219 4212453 EAST ASIA & THE PACFIC ESSENTIAL MEDICINE 42992 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 10000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 14007 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 2408103 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 139812 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 75000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 40733 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 20960 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 80876 CHECK/WIRE SOUTH AMERICA ESSENTIAL MEDICINE 12840 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 142894 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 16625 CHECK/WIRE 11 1 1 0 0 0 0 0 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PART III ACCOUNTING METHOD: 1 CHILDREN'S HOSPITAL BOSTON RESEARCH FINANCE PO BOX 414413 BOSTON MA 022414413 042774441 501(C)(3) 220451 ESSENTIAL MEDICINE HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC 6720-A ROCKLEDGE DRIVE STE 100 BETHESDA MD 20817 521317896 501(C)(3) 95325 ESSENTIAL MEDICINE TULANE UNIVERSITY 6823 ST CHARLES AVE NEW ORLEANS LA 70112 720423889 501(C)(3) 19800 ESSENTIAL MEDICINE PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 4265711 ESSENTIAL MEDICINE 4 0 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS CHAIR AND PRESIDENT 0 480557 0 78315 0 1800 0 33600 0 30402 0 624674 0 0 DAVID C KASLOW VICE CHAIR 0 381740 0 0 0 1800 0 33600 0 32581 0 449721 0 0 BRIAN N NEVILLE SECRETARY & TREASURER 0 222837 0 0 0 840 0 25743 0 8967 0 258387 0 0 OLIVIA D POLIUS TREASURER 0 177827 0 0 0 171006 0 21972 0 9995 0 380800 0 0 EDWARD M YOSHIDA SECRETARY 0 123405 0 0 0 16306 0 14365 0 3912 0 157988 0 0 JERRY KUO DIRECTOR 0 215187 0 0 0 400 0 26848 0 29105 0 271540 0 0 PRAVEEN RAJA DIRECTOR 0 372545 0 0 0 35995 0 28983 0 10854 0 448377 0 0 PART I, LINE 3 PVS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF OF ACCOUNTING SIGNED THE FORM. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PVS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PVS DOES NOT HAVE EMPLOYEES. PVS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVENUE CODE SECTION 509(A)(3), AND PVS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PVS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA ACS PLAZA 4TH FL LENANA RD PO BO NAIROBI KE EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH KE 501(C)(3) PATH 1 ORGANIZATION FOR APPROPRIATE TECHNOLOGY IN HEALTH-NIGERIA 9TH FL ST NICHOLAS HOUSE CATHOLI LAGOS NI EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH NI 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0